TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07330674: A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

Sponsor: Aptabio Therapeutics, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 68 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07330674 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07330674 Rescue Dossier →